Here are four things to know:
1. The lawsuit was brought by whistle-blower Ronald Streck, PharmD, a pharmacist and lawyer who previously served as the CEO of an association of prescription drug manufacturers.
2. The suit contends that from Jan. 1, 2007, to Dec. 31, 2013, Bristol-Myers fraudulently manipulated the calculation of the Medicaid rebate it owed. It is accused of underreporting the average manufacturer price, the price a wholesaler pays per unit. CMS uses this price to determine the amount a manufacturer owes the states.
3. U.S. District Judge Timothy Savage dismissed Bristol-Myer’s argument that the company didn’t act knowingly because the law mandating how to calculate rebates was ambiguous during the years in question.
4. “We conclude that Dr. Streck has alleged sufficient facts to state a false claims cause of action. He alleges facts which, if proven, will establish that BMS knowingly or, at least, recklessly reported and paid lower rebates than it owed. Therefore, we shall deny BMS’ motion to dismiss,” the lawsuit reads.
Read the full lawsuit here.
More articles on pharmacy:
Teva launches generic EpiPen for $300
Bayer considers sale of consumer health brands
Unilever wants to buy GlaxoSmithKline’s nutrition business: 5 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.